Lisata Therapeutics, Inc.
LSTA
Positions held
Your positionsLSTA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $12.96M | Enterprise value | $116,124 | Trailing P/E | — | Forward P/E | -1.03 |
| PEG | 118.40 | Price / book | 1.33 | Beta | 0.95 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -164.3% |
| Profit margin | 0.0% | ROE | -101.7% | ROA | -56.7% | Debt / equity | — |
| Current ratio | 3.69 | Free cash flow | -$8.10M | Analyst recommendation | none | Mean target | — |
| 52w high | $5.07 | 52w low | $0.99 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.1M | $0.0M | $0.1M | — |
| Op margin | — | — | -3079.0% | — | -6954.3% | — |
| Net income | -$2.9M | -$4.5M | -$3.0M | -$4.2M | -$4.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$4.0M | -$4.9M | -$3.1M | -$4.4M | -$4.9M | — |
- Operating margin expanded to -3079%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.2M | $1.0M | $0.0M | $0.0M |
| Op margin | -10711.2% | -2240.9% | — | — |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M |
Headlines — watch
• [WARN · balance sheet] Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?
News
2026-10-08 · Lisata Therapeutics wins new US patent for pancreatic cancer drug
2026-10-05 · Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
2026-10-05 · MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher
2026-09-24 · Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
2026-09-24 · MARKETS LIVE: Wall Street ends mixed as Hormuz hopes ease Middle East jitters
2026-09-23 · Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?
2026-09-17 · Lisata deal propels Marea’s drug pipeline to Wall Street
2026-09-17 · Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
2026-09-17 · Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Price (daily)
Full chart · RSI · MACD · patterns